Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03546686
Other study ID # IIT2018-01-McArthur-IPI
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 2018
Est. completion date May 2023

Study information

Verified date May 2018
Source Cedars-Sinai Medical Center
Contact Christina Abaya
Phone 310-423-5489
Email Christina.Abaya@cshs.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the impact of peri-operative cryoablation, ipilimumab and nivolumab versus standard pre-operative care on 3-year Distant Disease-Free Survival (DDFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after taxane-based neoadjuvant chemotherapy.


Description:

The purpose of this study is to determine the impact of peri-operative cryoablation, ipilimumab and nivolumab versus standard pre-operative care on 3-year Distant Disease-Free Survival (DDFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after taxane-based neoadjuvant chemotherapy. Our strategy combines two interventions: first we induce activation and maturation of dendritic cells and tumor-specific T cells by cross-presentation of tumor antigens via local destruction of tumor tissue by cryoablation. Second, we administer ipilimumab, a CTLA4 blocking antibody that enhances the magnitude and potency of the tumor specific T cell response, with nivolumab, a PD-1 blocking antibody that interferes with PD-1 mediated T-cell regulatory signaling. In this study, women with hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after neoadjuvant chemotherapy will be randomized to standard peri-operative management versus tumor cryoablation with peri-operative nivolumab and ipilimumab. Women undergoing either mastectomy or breast conserving surgery are eligible.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date May 2023
Est. primary completion date May 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Women age 18 years or older

- Confirmed histologic diagnosis of invasive adenocarcinoma of the breast

- Cedars Sinai pathology confirmation of invasive adenocarcinoma (reported or requested and pending)

- ER, PR and HER2 negative on outside or Cedars Sinai biopsy report, where ER and PR negative are defined as staining present in <1% of invasive cancer cells by IHC, and HER2-negative is defined as IHC 0-1+ or FISH <2.0. If ER, PR and HER2 status are not reported the results must be requested and pending.

- Operable tumor measuring =1.0 cm in maximal diameter

- Any nodal status

- Multifocal and multicentric disease is permitted.

- Synchronous bilateral invasive breast cancer is permitted

- No indication of distant metastases

- Total mastectomy or lumpectomy planned

- Tumor amenable to cryoablation as determined by a study radiologist

- ECOG performance status score of 0 or 1.

- Screening laboratory values must meet the following criteria:

- White blood cells (WBCs) = 2000/µL

- Absolute neutrophil count (ANC) = 1500/µL

- Platelets = 100 x 103/µL ii. Hemoglobin = 9.0 g/dL iii. Serum creatinine = 1.5 x ULN or creatinine clearance (CrCl) = 40 mL/min (if using the Cockcroft-Gault formula below): Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL

- AST/ALT = 3 x upper limit of normal (ULN)

- Bilirubin = 1.5 x ULN (except subjects with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL)

- Negative HIV screening test

- Negative screening tests for Hepatitis B and Hepatitis C. Patients with positive results that do not indicate true active or chronic infection may enroll after discussion and consensus agreement by the treating physician and principal investigator.

- Women of childbearing potential** (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab and ipilimumab to undergo five half-lives) after the last dose of investigational drug

- Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab

- Women must not be breastfeeding

- Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

- "Women of childbearing potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.

Women of childbearing potential (WOCBP) receiving nivolumab and ipilimumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days.

Exclusion Criteria:

- Medical history and concurrent diseases

- Autoimmune disease: subjects with a documented history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease are excluded from this study as are subjects with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]). Subjects with motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome) are excluded from this study.

- Any underlying medical or psychiatric condition, which in the opinion of the investigator, will make the administration of study drug hazardous or obscure the interpretation of AEs, such as a condition associated with frequent or poorly controlled diarrhea.

- Prohibited Treatments and/or Therapies

- Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). Brief periods of steroid use, for example for the management of chemotherapy-associated toxicities, are allowed. The use of corticosteroids on study is allowed for the treatment of immune related adverse events (irAEs) and other medical conditions including adrenal insufficiency.

- Any non-oncology vaccine therapy used for prevention of infectious diseases within 4 weeks prior to first dose of ipilimumab.

- Prior treatment with a CTLA4 inhibitor or PD1 inhibitor;

- Prior investigational agents within 4 weeks prior to ipilimumab/nivolumab;

- Prior therapy with any anti-cancer agents including chemotherapy, adjuvant chemotherapy, immunosuppressive agents, surgery or radiotherapy within 4 weeks prior to first dose of ipilimumab.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ipilimumab
Patients will receive ipilimumab 1-5 days prior to core biopsy and cryoablation.
Nivolumab
Patients will receive nivolumab 1-5 days prior to core biopsy and cryoablation.
Procedure:
Core Biopsy/Cryoablation
MRI-guided core biopsy and cryoablation 7-10 days prior to surgery.
Breast Surgery
Standard-of-care definitive surgery.

Locations

Country Name City State
United States Cedars Sinai Medical Center Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Cedars-Sinai Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Distant Disease-Free Survival Time (in months) between randomization and distant recurrence (i.e. evidence of breast cancer in any anatomic site that has either been histologically confirmed or clinically diagnosed as recurrent invasive breast cancer).
Time (in months) between randomization and second primary non-breast invasive cancer.
Time (in months) between randomization and date of death.
36 Months
Secondary Invasive Disease-Free Survival Time (in months) between randomization and ipsilateral invasive breast tumor recurrence (i.e. an invasive breast cancer involving the same breast parenchyma as the original primary lesion); or
Time (in months) between randomization and ipsilateral local-regional invasive breast cancer (i.e. an invasive breast cancer in the axilla, regional lymph nodes, chest wall and/or skin of the ipsilateral breast); or
Time (in months) between randomization and distant recurrance (i.e. evidence of breast cancer in any anatomic site - other than the two abovementioned sites - that has either been histologically confirmed or clinically diagnosed as recurrent invasive breast cancer); or
Time (in months) between randomization and contralateral invasive brease cancer; or
Time (in months) between randomization and second primary non-breast invasive cancer; or
Time (in months) between randomization and date of death
36 Months
Secondary Disease-Free Survival -Time (in months) between randomization and the date of the first occurrence of an invasive Disease Free Survival event including second primary non breast cancer events or contralateral or ipsilateral Ductal Carcinoma In Situ. 36 Months
Secondary Overall Survival -Time (in months) between randomization and death attributable to any cause. Patients who are alive, including lost to follow-up, at the time of the analysis will be censored at the last known alive date. 36 Months
Secondary Overall Safety Number of related adverse events based on CTCAE v.5.0 36 Months
See also
  Status Clinical Trial Phase
Recruiting NCT03095352 - A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Phase 2
Active, not recruiting NCT01472094 - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Phase 2
Recruiting NCT03667716 - COM701 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT03709134 - Genomic Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
Active, not recruiting NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Phase 1
Recruiting NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT03432429 - REI-EXCISE iKnife Study N/A
Active, not recruiting NCT02139358 - Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Recruiting NCT03615573 - Survey Study: Financial Impact of Breast Cancer Treatment
Completed NCT03323333 - Psychosocial Intervention Pilot for Partners in BRCA Testing N/A
Terminated NCT01649258 - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy Phase 1
Withdrawn NCT03285607 - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT01992432 - Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Completed NCT00759785 - A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) Phase 1
Not yet recruiting NCT03587259 - Innovation in Mammography: Tomosynthesis Pathways N/A